Ascites analysis by a microfluidic chip allows tumor-cell profiling
暂无分享,去创建一个
Hakho Lee | Ralph Weissleder | Vanessa M. Peterson | Cesar M. Castro | Jaehoon Chung | Cesar M Castro | Hakho Lee | Jaehoon Chung | R. Weissleder | M. Birrer | Adeeti V. Ullal | R. Penson | Michael J Birrer | Richard T Penson | Vanessa M Peterson | Nathan C Miller | Adeeti V Ullal | Maria D Castano | N. Miller | M. D. Castaño
[1] Hakho Lee,et al. Rare cell isolation and profiling on a hybrid magnetic/size-sorting chip. , 2013, Biomicrofluidics.
[2] R. Coleman,et al. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. , 2013, Gynecologic oncology.
[3] S. Kaye,et al. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research , 2013, Nature Reviews Cancer.
[4] K. Kinzler,et al. Evaluation of DNA from the Papanicolaou Test to Detect Ovarian and Endometrial Cancers , 2013, Science Translational Medicine.
[5] A. Jemal,et al. Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.
[6] E. Obermayr,et al. Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortium. , 2013, Gynecologic oncology.
[7] Jing Xie,et al. Clinical translation of folate receptor-targeted therapeutics , 2012, Expert opinion on drug delivery.
[8] Hakho Lee,et al. Microfluidic Cell Sorter (μFCS) for On‐chip Capture and Analysis of Single Cells , 2012, Advanced healthcare materials.
[9] M. Gore,et al. The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer , 2012, Molecular Cancer Therapeutics.
[10] Hakho Lee,et al. Sensitive and direct detection of circulating tumor cells by multimarker µ-nuclear magnetic resonance. , 2012, Neoplasia.
[11] P. Donahoe,et al. Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance , 2012, Proceedings of the National Academy of Sciences.
[12] B. Nolen,et al. Protein biomarkers of ovarian cancer: the forest and the trees. , 2012, Future oncology.
[13] M. Bologna. Biotargets of Cancer in Current Clinical Practice , 2012 .
[14] P. Yip,et al. Comprehensive Serum Profiling for the Discovery of Epithelial Ovarian Cancer Biomarkers , 2011, PloS one.
[15] R. Drapkin,et al. The new face of ovarian cancer modeling: better prospects for detection and treatment , 2011, F1000 medicine reports.
[16] Bei Zhang,et al. An overview of biomarkers for the ovarian cancer diagnosis. , 2011, European journal of obstetrics, gynecology, and reproductive biology.
[17] M. Quinn,et al. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell‐like profile , 2011, Journal of cellular biochemistry.
[18] V. Berezin,et al. The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling , 2011, EMBO molecular medicine.
[19] M. Loda,et al. A Comprehensive Analysis of PAX8 Expression in Human Epithelial Tumors , 2011, The American journal of surgical pathology.
[20] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[21] Sanjiv S Gambhir,et al. Early diagnosis of ovarian carcinoma: is a solution in sight? , 2011, Radiology.
[22] P. Boutros,et al. In-depth proteomics of ovarian cancer ascites: combining shotgun proteomics and selected reaction monitoring mass spectrometry. , 2011, Journal of proteome research.
[23] J. Baselga,et al. The Evolving War on Cancer , 2011, Cell.
[24] J. George,et al. Comparison of Expression Profiles in Ovarian Epithelium In Vivo and Ovarian Cancer Identifies Novel Candidate Genes Involved in Disease Pathogenesis , 2011, PloS one.
[25] R. Eskander,et al. Bevacizumab in the treatment of ovarian cancer , 2011, Biologics : targets & therapy.
[26] E. Lundberg,et al. Towards a knowledge-based Human Protein Atlas , 2010, Nature Biotechnology.
[27] D. Silasi,et al. High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. , 2010, American journal of obstetrics and gynecology.
[28] A. Goy,et al. Ovarian cancer biomarkers for molecular biosensors and translational medicine , 2010, Expert review of molecular diagnostics.
[29] Y. Allory,et al. Expression of follicle-stimulating hormone receptor in tumor blood vessels. , 2010, The New England journal of medicine.
[30] E. Dickerson,et al. Selective removal of ovarian cancer cells from human ascites fluid using magnetic nanoparticles. , 2010, Nanomedicine : nanotechnology, biology, and medicine.
[31] R. Drapkin,et al. PAX8 Reliably Distinguishes Ovarian Serous Tumors From Malignant Mesothelioma , 2010, The American journal of surgical pathology.
[32] L. Parker,et al. Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. , 2009, Gynecologic oncology.
[33] M. Birrer,et al. Ovarian Cancer: Markers of Response , 2009, International Journal of Gynecologic Cancer.
[34] A. Sood,et al. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. , 2009, Journal of the National Cancer Institute.
[35] D. Silasi,et al. Overexpression of Epithelial Cell Adhesion Molecule in Primary, Metastatic, and Recurrent/Chemotherapy-Resistant Epithelial Ovarian Cancer: Implications for Epithelial Cell Adhesion Molecule-Specific Immunotherapy , 2009, International Journal of Gynecologic Cancer.
[36] Raghu Kalluri,et al. The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.
[37] Robert C. Bast,et al. The biology of ovarian cancer: new opportunities for translation , 2009, Nature Reviews Cancer.
[38] J. Lee,et al. Immunocytochemical panel for distinguishing between adenocarcinomas and reactive mesothelial cells in effusion cell blocks , 2009, Diagnostic cytopathology.
[39] Afshin Mashadi-Hossein,et al. Multiplexed measurements of gene signatures in different analytes using the Nanostring nCounter™ Assay System , 2009, BMC Research Notes.
[40] Jennifer L. Osborn,et al. Direct multiplexed measurement of gene expression with color-coded probe pairs , 2008, Nature Biotechnology.
[41] C. Comin,et al. h-Caldesmon, Calretinin, Estrogen Receptor, and Ber-EP4: A Useful Combination of Immunohistochemical Markers for Differentiating Epithelioid Peritoneal Mesothelioma From Serous Papillary Carcinoma of the Ovary , 2007, The American journal of surgical pathology.
[42] George Coukos,et al. Tumor vascular proteins as biomarkers in ovarian cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] Chien-Nan Lee,et al. Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor. , 2006, Anticancer research.
[44] I. Eltoum,et al. Use of mesothelin as a marker for mesothelial cells in cytologic specimens. , 2006, Seminars in diagnostic pathology.
[45] N. Ordóñez. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study , 2006, Modern Pathology.
[46] A. Sood,et al. EphA2 as a target for ovarian cancer therapy , 2005, Expert opinion on therapeutic targets.
[47] J. Nesland,et al. The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas. , 2005, Gynecologic oncology.
[48] H. Lutz,et al. Isotype‐specific detection of ABO blood group antibodies using a novel flow cytometric method , 2005, British journal of haematology.
[49] D. Taylor,et al. Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects , 2005, British Journal of Cancer.
[50] Q. Ji,et al. Follicle stimulating hormone‐induced growth promotion and gene expression profiles on ovarian surface epithelial cells , 2004, International journal of cancer.
[51] P. Leung,et al. Overexpression of follicle-stimulating hormone receptor activates oncogenic pathways in preneoplastic ovarian surface epithelial cells. , 2004, The Journal of clinical endocrinology and metabolism.
[52] Geng Li,et al. Neutrophil CD64 Is a Sensitive Diagnostic Marker for Early-Onset Neonatal Infection , 2004, Pediatric Research.
[53] B. Karlan,et al. The prognostic significance of thrombocytosis in epithelial ovarian carcinoma. , 2004, Gynecologic oncology.
[54] A. Jazaeri,et al. Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[55] C. Pilarsky,et al. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. , 2002, The American journal of pathology.
[56] R. Attanoos,et al. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum , 2002, Histopathology.
[57] M. Pike,et al. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. , 2000, Gynecologic oncology.
[58] M. Schmidt,et al. Microfabrication in biology and medicine. , 1999, Annual review of biomedical engineering.
[59] N. Ordóñez. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. , 1998, The American journal of surgical pathology.
[60] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[61] J. Rheinwald,et al. Coexpression of simple epithelial keratins and vimentin by human mesothelium and mesothelioma in vivo and in culture. , 1984, Cancer research.
[62] M. D. Kendall,et al. Functional Histology. A Text and Colour Atlas , 1980 .
[63] G.B.D. Scott,et al. FUNCTIONAL HISTOLOGY: A TEXT AND COLOUR ATLAS , 1988, The Ulster Medical Journal.